跳至主要内容
临床试验/JPRN-UMIN000037851
JPRN-UMIN000037851已完成未知

Incidence of Hospitalized Infection in Elderly Patients with Rheumatoid Arthritis on bDMARDs and tsDMARDs: A Healthcare Data-Based Cohort Study - Incidence of Hospitalized Infection in Elderly Patients with Rheumatoid Arthritis on bDMARDs and tsDMARDs: A Healthcare Data-Based Cohort Study

CHUGAI PHARMACEUTICAL CO.,LTD. MEDICAL SCIENCE DEPT0 个研究点目标入组 5,506 人开始时间: 2019年9月1日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
5,506

研究概览

简要总结

Crude incidence rates (/100 person-years) of HIs were 3.99, 7.27, and 10.77, respectively. In the oldest group, aRRs (95% confidence interval) for HIs (b/tsDMARDs versus TCZ) were as follows: etanercept, 2.40 (1.24-4.61), adalimumab, 1.90 (0.75-4.83), golimumab, 1.21 (0.66-2.23), and abatacept, 0.89 (0.49-1.62). In the other age groups, the noticeable difference was a lower aRR of etanercept versus TCZ in the youngest group (0.30, 0.11-0.85).

研究设计

研究类型
Others,meta-analysis etc

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. Patients in hospital at baseline 2. Patients with other diseases indicated for the study therapy (behcet's disease, psoriasis, ankylosing spondylitis, kawasaki disease, crohn's disease, ulcerative colitis, juvenile idiopathic arthritis/adult still's disease, suppurative hidradenitis, castleman's disease, giant cell arteritis, takayasu's arteritis) at least once in the previous year

研究者

发起方
CHUGAI PHARMACEUTICAL CO.,LTD. MEDICAL SCIENCE DEPT

相似试验